Kanabidiol
 |
|
 |
|
| IUPAC ime | |
|---|---|
|
2-[(1R,6R)-6-izopropenil-3-metilcikloheks-2-en-1-il]-5-pentilbenzen-1,3-diol
|
|
| Klinički podaci | |
| Prodajno ime | Epidiolex |
| Drugs.com | Internacionalno ime leka |
| Pravni status | |
| Pravni status | |
| Farmakokinetički podaci | |
| Bioraspoloživost | 13–19% (oralno),[2] 11–45% (prosek 31%; inhalaciono)[3] |
| Poluvreme eliminacije | 9 h[2] |
| Identifikatori | |
| CAS broj | 13956-29-1  |
| ATC kod | None |
| PubChem | CID 644019 |
| IUPHAR/BPS | 4150 |
| ChemSpider | 24593618 |
| UNII | 19GBJ60SN5 |
| ChEBI | CHEBI:69478 |
| Hemijski podaci | |
| Formula | C21H30O2 |
| Molarna masa | 314.4636 |
|
|
|
|
| Fizički podaci | |
| Tačka topljenja | 66 °C (151 °F) |
| Tačka ključanja | 180 °C (356 °F) (opseg: 160–180 °C)[4] |
| (verify) | |
Kanabidiol (CBD) je kanabinoid prisutan u kanabisu. On je glavni sastojak biljke, koji sačinjava do 40% njenog ekstrakta.[5]
On pokazuje sedativno dejstvo u testovima na životinjama.[6] Neka istraživanja, međutim, indiciraju da CBD može da poveća budnost.[7] On može da umanji brzinu uklanjanja THC-a iz tela, verovatno putem ometanja metabolizma THC-a u jetri.
Pokazano je da omanjuje konvulzije, inflamaciju, anksioznost, i mučninu, kao i da inhibira rast ćelija kancera.[8] Nedavne studije su pokazale da je kanabidiol efektivan kao atipični antipsihotik u tretmanu šizofrenije.[9] Ispitivanja su takođe pokazala da olakšava simptome distonije.[10][11]
Novembera 2007. je objavljeno da CBD redukuje rast agresivnih ljudskih ćelija raka dojke in vitro i da umanjuje njihovu invazivnost.
References[уреди]
- ↑ DEA News Release, DEA Eases Requirements for FDA Approved Clinical Trials on Cannabidiol (December 23, 2015) ("CBD is a Schedule I controlled substance as defined under the CSA."), http://www.dea.gov/divisions/hq/2015/hq122315.shtml; Joseph T. Rannazzisi Deputy Assistant Administrator Drug Enforcement Administration Before the Caucus on International Narcotics Control, United States Senate, at 2 (June 24, 2015) (CBD is a Schedule I drug.); see also Frank Robison, Elvira Strehle-Henson, Cannabis Laws and Research at Colorado Institutions of Higher Education, COLO. LAW., OCTOBER 2015, AT 73, 76 ("[T]the DEA's position on CBD is clear—it is a Schedule I substance.").
- ↑ 2,0 2,1 Mechoulam R, Parker LA, Gallily R (2002). „Cannabidiol: an overview of some pharmacological aspects”. J Clin Pharmacol (Review). 42 (11 Suppl): 11S—19S. PMID 12412831. doi:10.1177/0091270002238789.
- ↑ Scuderi C, Filippis DD, Iuvone T, Blasio A, Steardo A, Esposito G (2009). „Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders”. Phytother Res (Review). 23 (5): 597—602. PMID 18844286. doi:10.1002/ptr.2625.
- ↑ Шаблон:MEDRS McPartland JM, Russo EB (2001). „Cannabis and cannabis extracts: greater than the sum of their parts?” (PDF). Journal of Cannabis Therapeutics. 1 (3/4): 103—132. doi:10.1300/J175v01n03_08.
- ↑ Grlić, Ljubiša (1962). „A comparative study on some chemical and biological characteristics of various samples of cannabis resin”. Bulletin on Narcotics. United Nations Office on Drugs and Crime (3): 37—46.
- ↑ Pickens JT (1981). „Sedative activity of cannabis in relation to its delta'-trans-tetrahydrocannabinol and cannabidiol content”. British Journal of Pharmacology. 72 (4): 649—56. PMC 2071638
. PMID 6269680. - ↑ Nicholson, AN (2004). „Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults” (fee required). J Clin Psychopharmacol. 24 (3): 305—13. ISSN 0271-0749. PMID 15118485. doi:10.1097/01.jcp.0000125688.05091.8f. Приступљено 3. 5. 2007. Непознати параметар
|coauthors=игнорисан [|author=се препоручује] (помоћ); Непознати параметар|month=игнорисан (помоћ) - ↑ Mechoulam, R. (21. 8. 2007). „Cannabidiol - recent advances”. Chemistry & Biodiversity. 4 (8): 1678—1692. PMID 17712814. doi:10.1002/cbdv.200790147. Непознати параметар
|coauthors=игнорисан [|author=се препоручује] (помоћ) - ↑ Zuardi, A.W (2006). „Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug” (PDF). Brazilian Journal of Medical and Biological Research. 39 (4): 421—429. PMID 16612464. doi:10.1590/S0100-879X2006000400001. Непознати параметар
|coauthors=игнорисан [|author=се препоручује] (помоћ) - ↑ Consroe, P.; Sandyk, R.; Snider, S. R. (1986). „Open label evaluation of cannabidiol in dystonic movement disorders”. The International journal of neuroscience. 30 (4): 277—282. PMID 3793381. doi:10.3109/00207458608985678.
- ↑ Snider, Stuart R.; Consroe, Paul (1985). „Beneficial and Adverse Effects of Cannabidiol in a Parkinson Patient with Sinemet-Induced Dystonic Dyskinesia”. Neurology (Suppl 1): 201.
Vidi još[уреди]
Spoljašnje veze[уреди]
- Erowid Compounds found in Cannabis sativa
